Ketorolac Trometamol Misom (Ketorolac Trometamol)

The drug reversibly blocks cyclooxygenase‑1 and cyclooxygenase‑2 enzymes in eye tissues, which lowers prostaglandin production. Reduced prostaglandins diminish the inflammatory response, leading to less pain, edema, and hyperemia in the ocular area.

The specific dosing regimen for Ketorolac Trometamol is determined by the prescribing clinician based on the patient’s condition, severity of inflammation, and response to therapy. Only a qualified healthcare professional should set the dose.

Safety data for Ketorolac Trometamol during pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ketorolac Trometamol is a potent COX‑1/COX‑2 inhibitor with a rapid onset of action, making it effective for acute post‑surgical inflammation. Compared with some other ocular NSAIDs, it may provide stronger pain relief but shares a similar safety profile, requiring careful monitoring for ocular surface effects.

Store the ophthalmic solution at ambient temperature, preferably below 25 °C, in its original container. Protect it from direct light and moisture, and keep the cap tightly closed when not in use to maintain sterility.

Ketorolac Trometamol is applied as eye drops directly onto the affected eye(s) according to the prescribing information. The patient should wash their hands before use, avoid touching the tip of the bottle to the eye or any surface, and follow the frequency recommended by the clinician.

Serious adverse events include corneal ulceration or perforation, severe allergic reactions such as anaphylaxis, significant increases in intra‑ocular pressure, and rare systemic hypersensitivity syndromes like Stevens‑Johnson syndrome. Any sudden vision changes or severe eye pain should prompt immediate medical evaluation.

Patients with known hypersensitivity to ketorolac, other NSAIDs, or any component of the formulation should avoid this product. It is also contraindicated in individuals with active corneal infections, severe ocular surface disease, or those who have had recent corneal surgery unless specifically directed by an eye specialist.